You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

SHINGRIX dosing and administration

Recommended dosing*

Go to Close Top

Non-live SHINGRIX is for intramuscular injection, given as a 2-dose series 1

Calendar icon

2-dose series:

The second dose of SHINGRIX can be administered any time between 2-6 months after the first dose.

2-dose series:

The second dose of SHINGRIX can be administered any time between 2-6 months after the first dose

2-dose series:

The second dose of SHINGRIX can be administered any time between 2-6 months after the first dose

2-dose series:

The second dose of SHINGRIX can be administered any time between 2-6 months after the first dose

2 vials icon

Supplied as 2 vials for reconstitution:

SHINGRIX is to be reconstituted only with the accompanying adjuvant suspension.

Thermometer icon

Refrigerate, do NOT freeze:

Prior to reconstitution, the vaccine should be stored between 2°C and 8°C. After reconstitution, the vaccine should be used promptly. If not possible, the vaccine is stable for 6 hours after reconstitution when refrigerated, after which it should be discarded.

Syringe icon

Intramuscular (IM) injection only:

Preferably in the deltoid muscle. 

 

Make sure your patients get both doses of SHINGRIX 1

Steps to consider to ensure your patients complete the 2-dose series 1

Doctor icon with speech bubble reading x2

Explain the importance of 2 doses to your patient 1

Calendar icon

Schedule the follow-up immediately:

Patients can receive the second dose any time between 2-6 months after the first dose. 1

Hand icon with string tied around finger

Reminders:

  • Once you set a date, have your patients place a reminder in their calendar.
  • Encourage your patients to visit SHINGRIX.ca to sign up to receive text or email reminders.

* Refer to the product monograph for complete dosing and administration information.

Reference:

  1. SHINGRIX Product Monograph. GlaxoSmithKline Inc., October 13, 2017.